Cytokinetics director awarded shares and stock options

Cytokinetics director Nancy Wysenski received new equity awards in the form of common shares and stock options.

Rhea-AI Filing Summary

Cytokinetics director Nancy Wysenski received new equity awards in the form of common shares and stock options. She was granted 2,851 shares of Common Stock at no purchase price, increasing her directly held stake to 33,917 shares. She also received a Non-Qualified Stock Option covering 4,301 shares of Common Stock with an exercise price of $77.1500 per share, exercisable into the same number of underlying shares and expiring on May 26, 2036. These awards are classified as grants or awards rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 7,152 shares

Grant/Award 2 txns

Insider Wysenski Nancy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	$0.00
Grant/Award	Common Stock	2,851	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 contracts (Direct); Common Stock — 33,917 shares (Direct)

Key Figures

Common shares granted: 2,851 shares Shares held after grant: 33,917 shares Option grant size: 4,301 options +2 more

5 metrics

Common shares granted 2,851 shares Award of Common Stock on May 27, 2026

Shares held after grant 33,917 shares Direct Common Stock holdings following transaction

Option grant size 4,301 options Non-Qualified Stock Option covering 4,301 underlying Common shares

Option exercise price $77.1500 per share Conversion or exercise price for Non-Qualified Stock Option

Option expiration date May 26, 2036 Expiration of Non-Qualified Stock Option

Key Terms

Non-Qualified Stock Option (Right to Buy), grant/award acquisition, Common Stock

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"The security title is listed as “Non-Qualified Stock Option (Right to Buy)”."

grant/award acquisition financial

"The transaction action is described as “grant/award acquisition”."

Common Stock financial

"Both the non-derivative security and underlying security are labeled as “Common Stock”."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYTK director Nancy Wysenski report in this Form 4 filing?

Nancy Wysenski reported receiving equity awards from Cytokinetics. She was granted 2,851 shares of Common Stock at no cost and a stock option for 4,301 shares, reflecting compensation-related grants rather than open-market trading activity.

How many CYTK common shares does Nancy Wysenski hold after the reported awards?

After the reported stock grant, Nancy Wysenski directly holds 33,917 shares of Cytokinetics Common Stock. This total includes her existing holdings plus the 2,851 newly awarded shares disclosed as a grant or award acquisition in the Form 4 filing.

What are the key terms of Nancy Wysenski’s new Cytokinetics stock option grant?

The new Non-Qualified Stock Option covers 4,301 shares of Cytokinetics Common Stock. It has an exercise price of $77.1500 per share, is tied to 4,301 underlying common shares, and is scheduled to expire on May 26, 2036.

Does this CYTK Form 4 show Nancy Wysenski buying or selling shares on the market?

No. The Form 4 shows grant or award acquisitions, not open-market trades. Wysenski received 2,851 shares and a 4,301-share stock option as compensation-related awards, with no reported market purchases or sales in this filing.

What type of security is the derivative reported in Nancy Wysenski’s CYTK filing?

The derivative security is a Non-Qualified Stock Option labeled as a “Right to Buy.” It allows her to purchase up to 4,301 Cytokinetics Common Stock shares at an exercise price of $77.1500 per share until its May 26, 2036 expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 07:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wysenski Nancy

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		2,851	A	$0	33,917	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Ms. Wysenski	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)